A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
NCT ID: NCT00316771
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
374 participants
INTERVENTIONAL
2005-11-30
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
P38 Inhibitor (4) 150mg
P38 Inhibitor (4) 150mg
150mg po qd
P38 Inhibitor (4) 25mg
P38 Inhibitor (4) 25mg
25mg po bid
P38 Inhibitor (4) 300mg
P38 Inhibitor (4) 300mg
300mg po qd
P38 Inhibitor (4) 50mg
P38 Inhibitor (4) 50mg
50mg po qd
P38 Inhibitor (4) 75mg
P38 Inhibitor (4) 75mg
75mg po bid
Placebo
Placebo
po bid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
P38 Inhibitor (4) 150mg
150mg po qd
P38 Inhibitor (4) 25mg
25mg po bid
P38 Inhibitor (4) 300mg
300mg po qd
P38 Inhibitor (4) 50mg
50mg po qd
P38 Inhibitor (4) 75mg
75mg po bid
Placebo
po bid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* active rheumatoid arthritis;
* current inadequate clinical response to methotrexate.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Paradise Valley, Arizona, United States
Tucson, Arizona, United States
Tucson, Arizona, United States
Tucson, Arizona, United States
Escondido, California, United States
Fair Oaks, California, United States
Loma Linda, California, United States
Riverside, California, United States
Upland, California, United States
Gainesville, Florida, United States
Ocala, Florida, United States
Ormond Beach, Florida, United States
Sarasota, Florida, United States
Tamarac, Florida, United States
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Macon, Georgia, United States
Nampa, Idaho, United States
Munster, Indiana, United States
South Bend, Indiana, United States
Wichita, Kansas, United States
Worcester, Massachusetts, United States
Traverse City, Michigan, United States
Omaha, Nebraska, United States
Toms River, New Jersey, United States
Albuquerque, New Mexico, United States
New Hartford, New York, United States
Rochester, New York, United States
Belmont, North Carolina, United States
North Fargo, North Dakota, United States
Tulsa, Oklahoma, United States
Bend, Oregon, United States
Camp Hill, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Wilkes-Barre, Pennsylvania, United States
Sioux Falls, South Dakota, United States
Jackson, Tennessee, United States
Knoxville, Tennessee, United States
Memphis, Tennessee, United States
Amarillo, Texas, United States
Bryan, Texas, United States
Carrollton, Texas, United States
Lubbock, Texas, United States
Norfolk, Virginia, United States
Everett, Washington, United States
Seattle, Washington, United States
Monroe, Wisconsin, United States
Caboolture, , Australia
Fitzroy, , Australia
Kippa-Ring, , Australia
Curitiba, , Brazil
Goiânia, , Brazil
São Paulo, , Brazil
Edmonton, Alberta, Canada
Winnipeg, Manitoba, Canada
St. John's, Newfoundland and Labrador, Canada
Mississauga, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Pointe-Claire, Quebec, Canada
Tallinn, , Estonia
Tallinn, , Estonia
Tallinn, , Estonia
Bad Nauheim, , Germany
Berlin, , Germany
Berlin, , Germany
Erfurt, , Germany
Erlangen, , Germany
Leipzig, , Germany
München, , Germany
Wiesbaden, , Germany
Athens, , Greece
Athens, , Greece
Heraklion, , Greece
Ioannina, , Greece
Thessaloniki, , Greece
Dublin, , Ireland
Dublin, , Ireland
Guadalajara, , Mexico
Mexico City, , Mexico
Monterrey, , Mexico
San Luis Potosí City, , Mexico
Auckland, , New Zealand
Christchurch, , New Zealand
Lower Hutt, , New Zealand
Elblag, , Poland
Sopot, , Poland
Szczecin, , Poland
Torun, , Poland
Warsaw, , Poland
Warsaw, , Poland
Bloemfontein, , South Africa
Cape Town, , South Africa
Durban, , South Africa
Johannesburg, , South Africa
Pretoria, , South Africa
A Coruña, , Spain
Barcelona, , Spain
Barcelona, , Spain
Córdoba, , Spain
Lugo, , Spain
Madrid, , Spain
Sabadell, , Spain
San Cristóbal de La Laguna, , Spain
Basingstoke, , United Kingdom
Cannock, , United Kingdom
Harrogate, , United Kingdom
Leeds, , United Kingdom
Metropolitan Borough of Wirral, , United Kingdom
Newcastle upon Tyne, , United Kingdom
Southampton, , United Kingdom
Wigan, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA18439
Identifier Type: -
Identifier Source: org_study_id